1. Home
  2. HNRG vs EVO Comparison

HNRG vs EVO Comparison

Compare HNRG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HNRG

Hallador Energy Company

HOLD

Current Price

$15.19

Market Cap

743.5M

Sector

Energy

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.58

Market Cap

778.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNRG
EVO
Founded
1949
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
743.5M
778.3M
IPO Year
1995
2007

Fundamental Metrics

Financial Performance
Metric
HNRG
EVO
Price
$15.19
$1.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$25.38
$7.00
AVG Volume (30 Days)
622.4K
41.4K
Earning Date
05-06-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
116.78
N/A
EPS
N/A
N/A
Revenue
$469,466,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$12.12
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
16.09
N/A
52 Week Low
$13.65
$1.60
52 Week High
$24.70
$4.27

Technical Indicators

Market Signals
Indicator
HNRG
EVO
Relative Strength Index (RSI) 45.42 28.43
Support Level $15.16 N/A
Resistance Level $16.97 $1.97
Average True Range (ATR) 0.66 0.05
MACD -0.15 -0.01
Stochastic Oscillator 36.02 2.70

Price Performance

Historical Comparison
HNRG
EVO

About HNRG Hallador Energy Company

Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: